Future of the drug label: Perspectives from a multistakeholder dialogue.

Regulating drugs does not end when market access has been granted. Monitoring drugs over the life cycle has become state of the art, inherent to evolving legislation and societal need. Here, we explore how the drug label could move along in a changing playing-field and become a sustainable label for the future. A dialogue between academia, government, the pharmaceutical industry and patient/societal organizations was organized by the Regulatory Science Network Netherlands. This is their view. © 2019 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Citation

Christine C Gispen-de Wied, Just Weemers, Wouter Boon, Peter G M Mol, Pieter Stolk. Future of the drug label: Perspectives from a multistakeholder dialogue. British journal of clinical pharmacology. 2019 Oct;85(10):2442-2445

Mesh Tags

PMID: 31317570

search → result